Baker Bros. Advisors’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Baker Bros. Advisors’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-256,375	Closed	-$84.5M	–	110
2014 Q1	$84.5M	Sell	256,375 -106,472	-29%	-$35.9M	1.07%	16
2013 Q4	$24.8M	Hold	362,847	–	–	0.35%	33
2013 Q3	$25M	Sell	362,847 -100,000	-22%	-$4.94M	0.36%	28
2013 Q2	$20.8M	Buy	+462,847	New	+$15.8M	0.41%	26

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Baker Bros. Advisors's ICPT Position: Q2 2014 in Review

Baker Bros. Advisors sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2014, closing a stake of 256,375 shares — an estimated $84.5M sold.

Baker Bros. Advisors first reported a position in ICPT in Q2 2013 and held it in 4 quarters. The position peaked at $84.5M in Q1 2014. 167 funds tracked by Wall St. Rank hold ICPT as of Q2 2014.

Baker Bros. Advisors reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2014 after selling out during the quarter.
Baker Bros. Advisors sold 256,375 Intercept Pharmaceuticals, Inc. shares in Q2 2014, an estimated $84.5M.
Baker Bros. Advisors first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2013 and held it in 4 quarters.
Baker Bros. Advisors's Intercept Pharmaceuticals, Inc. position peaked at $84.5M in Q1 2014.
167 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2014.

Based on Baker Bros. Advisors's 13F filing for Q2 2014, filed 14 Aug 2014.